Comprehensive analysis of Baroda BNP Paribas Health and Wellness Fund-Reg(IDCW) (45770) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
Baroda BNP Paribas Asset Management India Ltd
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
A comprehensive at-a-glance view of key mutual fund health indicatorsHover or click any card to view detailed metrics
Weak Returns
High Risk
High Expenses
Equity Focused
New Team
Below Average
Showing 1Y NAV history
Performance across different time periods
Fund shows concerning indicators. Exercise caution before investing.
Consider waiting for better market conditions or explore alternatives.
Fund shows concerning indicators. Exercise caution before investing.
Consider waiting for better market conditions or explore alternatives.
Recent performance momentum
Outperformance vs benchmark
Market exposure level
Risk-adjusted returns
Assets under management
Fund manager experience
Historical performance consistency
Fund management costs
This fund has underperformed its benchmark by 48.32% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Industry | % Assets |
|---|---|---|
| C C I | Debt Others | 13.52% |
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 12.09% |
| Divis Laboratories Ltd | Pharmaceuticals | 5.90% |
| Apollo Hospitals Enterprise Ltd | Healthcare | 5.59% |
| Mankind Pharma Ltd | Pharmaceuticals | 5.51% |
| Cipla Ltd | Pharmaceuticals | 5.16% |
| Max Healthcare Institute Ltd | Healthcare | 4.78% |
| Fortis Healthcare Ltd | Healthcare | 4.03% |
| Gland Pharma Ltd | Pharmaceuticals | 3.60% |
| Abbott India Ltd | Pharmaceuticals | 3.59% |
Compare against Sectoral / Thematic category average
This comparison shows how the fund performs relative to the Sectoral / Thematic category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Sectoral / Thematic category
| Fund Name | NAV | 1W | 1M |
|---|---|---|---|
| Aditya Birla SL MNC Fund - Direct (G) | ₹1540.61 | 0.88% | 1.47% |
| Aditya Birla SL MNC Fund - (G) | ₹1383.22 | 0.86% | 1.41% |
| Nippon India Banking&Financial Services-Dir(G) | ₹662.94 | -0.55% | -1.32% |
| Nippon India Banking&Financial Services-Dir(Bonus) | ₹662.94 | -0.55% | -1.32% |
| Nippon India Banking&Financial Services (G) | ₹606.00 | -0.56% | -1.39% |
| Nippon India Banking&Financial Services (Bonus) | ₹606.00 | -0.56% | -1.39% |
| Nippon India Pharma Fund - Direct (G) | ₹574.98 | 0.06% | -0.43% |
| Nippon India Pharma Fund - Direct (Bonus) | ₹574.98 | 0.06% | -0.43% |
| Franklin India Technology Fund - Direct (G) | ₹565.29 | -0.79% | 2.73% |
| ICICI Pru FMCG Fund - Direct (G) | ₹542.41 | 1.67% | 1.69% |
A seasoned investment professional with over 0 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.